VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
EXEL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
EXELExelixis, Inc.
$69.57$17.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. EXEL
  4. Financial Ratios

Exelixis, Inc. (EXEL) Financial Ratios

Latest Ratios: P/E Ratio 20.1x · EV/EBITDA 16.7x · ROE 35.5%. (1999–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

EXEL Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$17.5B$12.3B$10.1B$7.7B$5.2B$5.9B$6.4B$5.6B$6.2B$9.5B$3.7B
Enterprise Value$17.2B$12.0B$10.0B$7.6B$4.9B$5.3B$6.1B$5.3B$5.9B$9.3B$3.8B
P/E Ratio →20.1015.6819.3036.9128.6425.3957.3417.278.9062.04—
P/S Ratio7.005.294.644.213.234.116.465.747.2120.9619.51
P/B Ratio9.075.684.483.412.092.673.403.294.7833.2841.82
P/FCF15.1814.5515.8745.2723.2217.5135.7310.8016.0965.6518.26
P/OCF19.7813.8914.3723.1414.3614.7030.5410.5314.8057.2718.11

P/E links to full P/E history page with 30-year chart

EXEL EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—5.164.634.173.043.696.195.516.8520.5919.71
EV / EBITDA16.6613.2915.8438.8522.0117.6451.2814.1213.1055.75—
EV / EBIT19.6913.4114.5429.6620.8918.0155.5313.4013.3455.75—
EV / FCF—14.1815.8344.8421.8415.7434.2210.3815.3064.4918.44

EXEL Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin96.4%96.4%96.5%96.0%96.4%96.3%96.3%96.6%96.9%96.7%96.6%
Operating Margin37.6%37.6%27.9%9.3%12.5%20.0%11.1%38.2%51.4%36.7%-14.7%
Net Profit Margin33.7%33.7%24.0%11.4%11.3%16.1%11.3%33.2%80.8%34.1%-36.7%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE35.5%35.5%23.1%8.7%7.8%11.3%6.3%21.6%87.8%82.4%-78.6%
ROA27.0%27.0%17.7%6.9%6.4%9.7%5.6%19.4%66.4%24.6%-15.1%
ROIC32.1%32.1%20.6%5.9%8.0%13.3%5.4%22.5%59.6%102.4%-16.1%
ROCE35.0%35.0%23.7%6.5%8.0%13.6%6.0%24.2%47.3%38.3%-9.3%

EXEL Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.080.080.090.080.080.020.030.030.010.052.12
Debt / EBITDA0.190.190.300.970.860.170.410.130.030.09—
Net Debt / Equity—-0.14-0.01-0.03-0.12-0.27-0.14-0.13-0.23-0.590.42
Net Debt / EBITDA-0.34-0.34-0.04-0.37-1.40-1.98-2.27-0.57-0.67-1.01—
Debt / FCF—-0.37-0.04-0.43-1.39-1.77-1.51-0.42-0.78-1.170.18
Interest Coverage—————————19.25-1.12

Net cash position: cash ($482M) exceeds total debt ($173M)

EXEL Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio3.563.563.633.344.995.437.067.088.504.211.74
Quick Ratio3.503.503.583.304.895.356.966.998.414.151.73
Cash Ratio2.612.612.752.524.034.355.905.976.573.371.55
Asset Turnover—0.820.740.620.520.550.460.510.600.690.32
Inventory Turnover3.863.863.404.191.741.921.732.572.682.261.96
Days Sales Outstanding—45.1444.6747.3548.6672.6359.4644.9169.5865.5077.11

EXEL Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield5.0%6.4%5.2%2.7%3.5%3.9%1.7%5.8%11.2%1.6%—
FCF Yield6.6%6.9%6.3%2.2%4.3%5.7%2.8%9.3%6.2%1.5%5.5%
Buyback Yield5.4%7.7%6.5%7.1%0.0%0.0%0.0%0.0%0.1%0.1%0.1%
Total Shareholder Yield5.4%7.7%6.5%7.1%0.0%0.0%0.0%0.0%0.1%0.1%0.1%
Shares Outstanding—$282M$296M$321M$325M$322M$318M$315M$313M$312M$251M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Working capital timing dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Discount Multiples Imply Continued Earnings Growth

Based on reported figures, Exelixis trades at 24.7x trailing P/E but 19.1x forward P/E and a PEG of 0.48, suggesting the market is pricing in earnings growth that the trailing multiple alone does not fully reflect.

The gap between trailing and forward P/E implies consensus expects meaningful earnings expansion, and a PEG below 1.0 typically signals growth is priced conservatively relative to the earnings trajectory. Against a P/B of 8.96 and P/S of 7.44, the valuation is rich on book and sales measures, which is consistent with a high-margin royalty-style model where asset values understate earning power. Investors should monitor whether forward estimates hold, since the discount depends on sustained growth rather than current figures.

Operating Margin Expansion Outpaces Revenue Growth

As reported in financial statements, operating margin widened from 25.2% in 2024Q3 to 40.8% in 2026Q3 while gross margin stayed near 96%, indicating overhead discipline is driving earnings rather than pricing on cost of sales.

With gross margin structurally saturated between 95.6% and 97.2%, the operating margin trajectory reflects operating leverage on a largely fixed cost base rather than improving unit economics. Net margin of 33.1% sits meaningfully below operating margin, which suggests a tax or non-operating drag that warrants further review in the income statement. The operating margin of 40.8% is well above much of the peer set on a relative basis, though a concentrated royalty or license stream may be doing much of the work.

Returns Recovering From Multi-Year Trough

Based on Exelixis's reported figures, ROIC rebuilt from 4.7% in 2024Q3 to 11.8% in 2026Q3 and ROE climbed to 11.9%, pointing to a compounding return trajectory after a sustained decline.

The recovery in ROIC appears driven more by margin expansion than by capital efficiency, since asset turnover remains low at 0.26. An ROIC of 11.8% is solid but well below peer leaders such as Incyte at 51.1%, which suggests the company's capital base is less productive per dollar than the strongest peers. Sustained compounding would require margins to hold while the equity base, which has contracted, stabilizes.

Minimal Leverage Limits Financial Risk

According to recent SEC filings, Exelixis's debt-to-equity ratio sits near 0.09 with total debt declining to $162.2M, while debt-to-EBITDA eased from 1.35 to 0.59, suggesting leverage is not a binding constraint.

Declining debt alongside improving EBITDA coverage points to a balance sheet that is becoming less encumbered over time. Interest coverage is not reported in the supplied data, so debt service comfort must be inferred from the leverage trend rather than measured directly. Refinancing or covenant risk appears low on the reported figures, though the lumpy cash base means liquidity should be read alongside leverage.

Strong Current Ratio Masks Volatile Cash Base

Based on Exelixis's reported figures, the current ratio held between 3.21 and 4.27 across ten quarters, yet cash swung from $164.4M to $482.5M, indicating the liquidity cushion is real but uneven.

A current ratio above 3.0 and a quick ratio nearly equal to it indicate that inventory is immaterial to liquidity, consistent with a non-manufacturing revenue base. The volatility in cash balances, however, suggests quarterly liquidity depends on the timing of receipts and deployment, particularly buybacks. Under a severe stress scenario, the balance sheet would likely hold given low debt, though the stability of the cash position warrants monitoring.

Peer Profitability Gap Questions Durability

As reported in financial statements, Exelixis's 40.8% operating margin and 33.1% net margin trail Halozyme's 58.4% operating margin, which may indicate current earnings rest on a narrower revenue base than headline ratios imply.

The most commonly misapplied metric for a royalty-weighted biotech is trailing P/E, because a single license or milestone receipt can inflate or depress earnings in a quarter without reflecting recurring economics. Operating margin similarly obscures how much of the figure depends on lumpy revenue recognition. Investors should adjust for non-recurring receipts and weigh free cash flow alongside earnings, since working capital timing has produced volatile quarterly cash conversion.

Download Financial Ratios Data

Includes 30+ ratios · 27 years · Updated daily

Consensus & Technical Research Suite
Open EXEL Terminal

EXEL Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

EXEL — Frequently Asked Questions

Quick answers to the most common questions about buying EXEL stock.

What is Exelixis, Inc.'s P/E ratio?

Exelixis, Inc.'s current P/E ratio is 20.1x. The historical average is 28.0x. This places it at the 50th percentile of its historical range.

What is Exelixis, Inc.'s EV/EBITDA?

Exelixis, Inc.'s current EV/EBITDA is 16.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.9x.

What is Exelixis, Inc.'s ROE?

Exelixis, Inc.'s return on equity (ROE) is 35.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -31.9%.

Is EXEL stock overvalued?

Based on historical data, Exelixis, Inc. is trading at a P/E of 20.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Exelixis, Inc.'s profit margins?

Exelixis, Inc. has 96.4% gross margin and 37.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Exelixis, Inc. have?

Exelixis, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.